Background-Several bone marrow-derived cell populations may have angiogenic activity, including cells termed endothelial progenitor cells. Decreased numbers of circulating angiogenic cell populations have been associated with increased cardiovascular risk. However, few data exist from large, unselected samples, and the genetic determinants of these traits are unclear. Methods and Results-We examined the clinical and genetic correlates of early-outgrowth colony-forming units (CFUs) in 1799 participants of the Framingham Heart Study (mean age, 66 years; 54% women). Among individuals without cardiovascular disease (nϭ1612), CFU number was inversely related to advanced age (Pϭ0.004), female sex (Pϭ0.04), and triglycerides (Pϭ0.008) and positively related to hormone replacement (Pϭ0.008) and statin therapy (Pϭ0.027) in stepwise multivariable analyses. Overall, CFU number was inversely related to the Framingham risk score (Pϭ0.01) but not with prevalent cardiovascular disease. In genome-wide association analyses in the entire sample, polymorphisms were associated with CFUs at the MOSC1 locus (Pϭ3.3ϫ10 Ϫ7 ) and at the SLC22A3-LPAL2-LPA locus (Pϭ4.9ϫ10 Ϫ7 ), a previously replicated susceptibility locus for myocardial infarction. Furthermore, alleles at the SLC22A3-LPAL2-LPA locus that were associated with decreased CFUs were also related to increased risk of myocardial infarction (Pϭ1.1ϫ10 Ϫ4 ). Conclusions-In a community-based sample, early-outgrowth CFUs are inversely associated with select cardiovascular risk factors. Furthermore, genetic variants at the SLC22A3-LPAL2-LPA locus are associated with both decreased CFUs and an increased risk of myocardial infarction. These findings are consistent with the hypothesis that decreased circulating angiogenic cell populations promote susceptibility to myocardial infarction. (Circ Cardiovasc Genet. 2011; 4:296-304.)
studies suggest that EPCs, variably defined, may be capable of promoting neovascularization in the setting of arterial ischemia 4 -6 and reendothelialization after mechanical arterial injury, 7 though more recent data are conflicting on this point. 8, 9 
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Prior studies have reported an inverse association of EPC-related phenotypes with cardiovascular risk factors and aggregate cardiovascular risk, 10, 11 although these associations are not consistent across all studies. 12, 13 EPC phenotypes have also been inversely correlated with subclinical markers of endothelial dysfunction 11,14 -16 and incident cardiovascular events. 17, 18 However, most prior investigations have been small case-control studies or case series that have varied widely with respect to patient selection and illness acuity. 19, 20 Furthermore, in the absence of EPC-specific markers, 21 many different methods have been used in attempts to quantify EPCs, including in vitro colony assays, fluorescent microscopy, and flow cytometry for endothelial and hematopoeitic cell surface markers. 22 These methods have limited ability to differentiate true endothelial precursor cells from other cell types with proangiogenic and vasculogenic properties. 3, 23 In fact, recent evidence suggests that phenotypes previously defined as EPCs probably include several different cell populations of varying lineage and with distinct functional roles with respect to postnatal vasculogenesis. 21,24 -26 A widely used EPC-related phenotype is early-outgrowth colony-forming units (CFUs), which arise from culturing peripheral blood mononuclear cells as originally described by Hill et al. 11 Although CFUs are not direct endothelial precursors, prior experimental studies suggest that CFUs are highly angiogenic and that their formation appears to be dependent on cell populations with known vascular promoting activities, including monocytes and T cells. 3, 24, 25, 27 Furthermore, CFUs have been inversely related to cardiovascular risk factors, 11 vascular dysfunction, 11 and adverse cardiovascular outcomes 17 in selected patient samples. As such, CFUs may represent an important cell-based marker of circulating angiogenic potential and risk for cardiovascular disease (CVD). Therefore, we sought to investigate the clinical correlates of CFUs in a large, community-based, ambulatory cohort. In addition, we applied a genome-wide analysis to identify potential genetic determinants of CFU variation. We also examined whether genetic variants associated with lower CFU number might, in turn, be related to higher cardiovascular risk, which would support the hypothesis that decreased number of circulating angiogenic cells and CVD can arise from shared genetic mechanisms.
Methods
Because of the heterogeneity in phenotypes referred to as EPCs, 8 we use CFUs to describe our early-outgrowth colony measurement in the interest of clarity. We use terms such as "EPC phenotypes" or "EPC-related traits" when referring to findings in the broader literature that draw on diverse definitions of EPCs.
Study Sample
The Framingham Heart Study was established in 1948, when 5209 residents of Framingham, MA, were enrolled in a longitudinal cohort study designed to identify risk factors for CVD. 28 In 1971, an additional 5124 participants (offspring of the original cohort subjects, and their spouses) were enrolled in the Framingham Offspring Study. 29 All Offspring study participants receive routine examinations approximately every 4 years. Of the 3021 participants who attended the eighth Offspring examination cycle (2005 through 2008), 1799 had assessment of CFUs. Individuals with and without CFU assessment had similar clinical characteristics and cardiovascular risk factor profiles (online-only Data Supplement Table 1 ). Of the total sample with CFUs assessed, the majority (nϭ1612) of participants did not have a documented history of CVD (history of myocardial infarction [MI], coronary insufficiency, stroke, and heart failure) ( Table 1) . Participants underwent a standardized medical examination and laboratory assessment of cardiovascular risk factors (online-only Data Supplement, Methods). All participants were also followed longitudinally through 2007, during which data regarding incident cardiovascular events were collected and adjudicated (online-only Data Supplement, Methods). All participants gave informed consent. The institutional review board of the Boston University School of Medicine approved all study protocols.
Assessment of Early-Outgrowth CFUs
All blood specimens for the CFU assay were collected from fasting participants in the morning between 8 and 9 AM. Each blood sample underwent initial centrifugation, and the resulting buffy coat was further processed for CFU characterization within 4 hours of specimen collection according to an established protocol, 11 with modifications (online-only Data Supplement, Methods).
Genotyping
Genotyping was performed in FHS by Affymetrix (Santa Clara, CA), using the Affymetrix 500K GeneChip array and a custom-designed 
Statistical Analyses
Because it had a skewed distribution that included zero values, square-root transformation of CFUs yielded the best normally distributed data (skewnessϭ1.12) and was performed before analyses. We also tested logarithmic transformation (after adding 1 to account for zero values), but this resulted in overcorrection of right skewness, leading to a left-skewed distribution (skewnessϭϪ0.59).
We analyzed clinical correlates of CFUs on the basis of prior reports 12, 17 in 1612 participants free of CVD at the time of the assay. Age-and sex-adjusted linear regression models were used to examine the relation of CFUs with the following covariates: age, sex, systolic blood pressure, diastolic blood pressure, body mass index, fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, log-triglycerides, hypertension (systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg or taking antihypertensive medications), diabetes, smoking status, and selected medications (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, ␤-blockers, calcium channel blockers, diuretics, hormone replacement therapy (HRT), and statins). Stepwise regression models were used to examine multivariable associations of CFUs with variables having probability values Ͻ0.10 in the age-and sex-adjusted analyses. We also performed analyses relating CFUs to the Framingham risk score 31 in the sample free of CVD and then in men and women separately (of the same sample). In the total sample, we examined the relations of CFUs with prevalent CVD. Our sample size, with nϭ1799 observations and a fixed significance level ␣ϭ0.05, afforded 80% power to detect a significant result for a variable accounting for 0.44% of the variance in CFUs. A probability value of Ͻ0.10 was the criterion for covariates to enter and remain in stepwise regression models, and a 2-tailed probability value of Ͻ0.05 was considered significant.
In secondary analyses, we repeated the following analyses, using generalized estimating equations 32 to account for correlations among related individuals (siblings) in the study sample (SAS PROC GENMOD): (1) age-and sex-adjusted analyses of the relation between CFUs and the clinical covariates listed above (and in online-only Data Supplement Table 2 ) and (2) a single multivariable model adjusting for the clinical covariates that were associated with CFUs in age-and sex-adjusted analyses with a probability value threshold of at least Ͻ0.10. All analyses were performed using SAS statistical software, version 9.1.3.
To estimate heritability, the residuals of the age-and sex-specific model were rank-normalized, and the heritability was computed using the Sequential Oligogenic Linkage Analysis Routines (SOLAR, version 2.1.4). 33
Genetic Association Analyses
To maximize statistical power, we performed the genetic association analyses in the total study sample, including participants with previous CVD. To account for potential confounding by population stratification, we used principal components analysis to define principal components of ancestry; 34 because no principal components were associated with CFUs, adjustment for these components was not included in regression modeling. We created age-and sex-adjusted residuals of square root-transformed CFUs, using models that did not account for family structure, because age-and sex-adjusted residuals from models that did and did not account for family structure were highly correlated (rϭ0.99996, PϽ0.0001). These residuals were tested for association with each imputed (Ϸ2.5 million) single-nucleotide polymorphism (SNP) under an additive genetic model using the linear mixed effects model in the R-kinship package to account for relatedness. 35 We restricted our analyses to additive genetic models to limit the number of statistical tests. The use of analyses that assume an additive model is considered relatively robust to misspecification of the true model for a quantitative trait such as CFUs. 36 We selected an a priori genome-wide statistical significance threshold of 5ϫ10 Ϫ7 , which is the threshold used by the Wellcome Trust Case-Control Consortium and accounts for Ϸ1 million independent tests, given the known high correlation among the majority of identifiable SNPs. 37 For 2.5 million tests, this threshold provides an expectation of Ͻ1.25 false-positive results across the genome. A threshold for moderate genome-wide statistical significance (5ϫ10 Ϫ6 ) 37 was considered to identify all potential loci of interest. For the top chromosomal loci, we verified that each locus had a directly genotyped SNP with a similar association to that observed with the most significantly associated imputed SNP. Regional plots for top hits showed high linkage disequilibrium (LD) between the directly genotyped SNP (red diamond) and the imputed SNP with the lowest probability values (squares with darker red coloring denote high LD; online-only Data Supplement Figure 1 ). Given the uniqueness of measuring CFUs in large samples, a replication sample was not available for the present study. Therefore, in the absence of a replication sample, we sought to further determine if any genetic determinants of CFUs identified in the study sample were, in turn, related to MI. Thus, SNPs with associations with CFUs were tested in survival analyses, using an empirical robust (sandwich) standard error, for their association with adjudicated recognized MI in both original and offspring cohorts (nϭ4449) occurring over 36 years of follow-up between 1971 and 2007 (online-only Data Supplement Figure 2 ).
Results
Clinical characteristics of the total sample and the subset without prevalent CVD are shown in Table 1 . The mean (ϮSD) age was 66Ϯ9 years, and 54% were women. The distribution of absolute CFU counts in the total sample is shown in the online-only Data Supplement Figure 3 , and there was no significant difference in CFU distribution between individuals with and without prevalent CVD as well as individuals with and without a history of MI. In the total sample, the median (interquartile range) CFU number was 38.9 (45.3) per well.
Clinical Correlates
In age-and sex-adjusted analyses performed in individuals without prevalent CVD, CFUs were inversely associated with older age, female sex, higher triglycerides, and HRT ( Table  2 ). Although women overall had fewer CFUs than men, CFU number in women taking HRT was not significantly different from that of men (Pϭ0.154). The age-and sex-adjusted associations remained significant in multivariable-adjusted analyses, in which CFUs were also higher among individuals receiving statin therapy. Overall, however, clinical covariates accounted for a small proportion of the total variation in CFUs (R 2 ϭ0.02).
When age-and sex-adjusted analyses were repeated using generalized estimating equations (accounting for 308 sibships: 221 sibships of 2 persons, 68 sibships of 3 persons, 13 sibships of 4 persons, and 6 sibships of 5 persons), results were similar (online-only Data Supplement Table 2 ). Results of multivariable-adjusted analyses performed using generalized estimating equations were also similar.
The sex-specific, predicted 10-year coronary risk based on the Framingham Risk Score was inversely associated with CFUs (Pϭ0.01) ( Figure 1 ). There was no significant interaction by sex (P for interactionϭ0.91). Only 10% of participants attending this examination had prior CVD, and CFUs were not associated with prior CVD after adjustment for conventional risk factors (Pϭ0.67). Estimated heritability was 2.2% in age-and sex-adjusted analyses, similar to the variation attributable to measured clinical covariates.
Genetic Correlates
The quantile-quantile plot from genome-wide association analyses ( Figure 2 ) shows a deviation toward excess associations with low probability values, suggesting the presence of significant genetic association. The genomic inflation factor () was 1.027. Figure 3 shows the probability values (Ϫlog base 10 scale) for the associations of the individual SNPs with CFUs (using age-and sex-adjusted residuals of square root-transformed CFUs), plotted against chromosomal posi-tion. The individual imputed variants with the strongest associations are listed in Table 3 . Polymorphisms in the following 2 regions had genome-wide significant associations with CFUs: rs6693017 (Pϭ3.25ϫ10 Ϫ7 ) at chromosome position 1q41 (within or near the MOSC1 gene) and rs394352 (Pϭ4.92ϫ10 Ϫ7 ) at chromosome position 6q26-q27 (within SLC22A3). SNPs at 3 additional loci had suggestive associ- Data are from the subset of individuals without known CVD (nϭ1612). The CFU variable is square root-transformed. Coefficients (standard error) represent change in the dependent variable for an increase in the value of the covariates shown (by 1 SD for continuous variables). In age-and sex-adjusted models, the association with age is adjusted for sex and the association with sex is adjusted for age. Table 3 ). The SNP near the MOSC1 gene were in LD with one another (r 2 Ն0.91, CEU HapMap release 22), as were SNPs near the SLC22A3 gene (r 2 Ն0.81). We also repeated the genome-wide association study using age and sex as covariates in the models (instead of using age-and sex-adjusted residuals) as well as an analysis that additionally adjusted for all significant clinical correlates of CFUs (log triglycerides, statin therapy, and HRT in addition to age and sex); these did not alter the associations with the above loci significantly, and ␤ coefficients and standard errors were largely unchanged (data not shown).
Several variants at the SLC22A3 locus that were associated with CFUs were significantly associated with MI in the Framingham sample (probability values ranging from 1.08ϫ10 Ϫ4 to 8.48ϫ10 Ϫ4 ; Table 4 ). The SNPs with the lowest probability values for association with CFUs were highly correlated with those having the lowest probability values for association with MI (r 2 ϭ0.579 to 0.961; onlineonly Data Supplement Table 4 ). Furthermore, the direction of effect for each allele was consistent for these SNPs: Alleles associated with higher CFUs were associated with lower risk for MI, and alleles associated with lower CFUs were associated with higher MI risk. SNPs at the 1q41 locus were not associated with MI in Framingham.
Discussion
In the present study, we report the clinical and genetic correlates of early-outgrowth CFUs in a community-based sample of predominantly healthy men and women. Our principal findings are 3-fold. First, we observed modest associations between CFUs and traditional cardiovascular risk factors. Lower number of CFUs was related to higher overall risk factor burden, as reflected by the Framingham Risk Score, although this was largely attributable to the inverse relation of CFUs with age. Second, we identified novel associations between CFUs and genetic variants at several loci. Third, variants at one of these loci (SLC22A3) were not only associated with lower CFUs but were also associated with higher MI risk. Taken together, our data suggest that variation in CFUs may represent a mechanism by which cardiovascular risk is modulated by genetic as well as acquired factors. Interest in the determinants of variation in EPC phenotypes in humans stems from the previously reported association of EPC-related traits with cardiovascular risk and the biological hypothesis that chronic depletion of EPC-like cells leads to an impaired capacity for endothelial repair. The present investigation used a widely accepted method for identifying earlyoutgrowth CFUs and comprises the largest cohort of individuals with an assessment of circulating angiogenicrelated traits studied to date. Other strengths of the study include the comprehensive ascertainment of cardiovascular risk factors, the focus on ambulatory individuals without acute illnesses that could lead to mobilization of proangiogenic cells, 19, 20 and the availability of extensive genetic data.
Clinical Correlates
We found relatively modest associations between earlyoutgrowth CFUs and conventional cardiovascular risk factors. In our study, a lower number of CFUs was observed in older individuals and women. Decreased number of cells considered to be EPCs with older age has been observed in multiple prior studies, 12, 38 although underlying mechanisms remain unclear. Certain EPC phenotypes may be particularly susceptible to intrinsic senescence, as reflected by telomere shortening. 39 However, the degree to which senescence affects CFUs is unknown. 40 Reduced number of EPC-like cells in women has been reported in some studies 12 but not others. 41, 42 Studies that failed to find any effect of sex were considerably smaller than the present study and included younger women. The women in our study were almost entirely postmenopausal, suggesting the possibility of a sex hormone effect. Indeed, we found that HRT was associated with higher CFUs, 12 such that women taking HRT had CFU numbers comparable to those in men. Experimental studies suggest that estrogens may enhance EPC-related traits by reducing apoptosis of progenitor cells 43 and stimulating endothelial nitric oxide synthase-dependent mobilization of progenitor cells. 44 Therefore, estrogen withdrawal in postmenopausal women may lead to decreased CFUs as well.
We found that, consistent with prior experimental and clinical data pertaining to other EPC phenotypes, 45, 46 CFUs were higher in individuals taking statin medications. Notably, we also observed that CFUs were inversely associated with triglycerides but not with other lipid traits such as LDL cholesterol. These findings support the hypothesis that one of the nonlipid benefits of statins in cardiovascular prevention could be their influence on circulating angiogenic cell number. Our results are consistent with a previously reported inverse association between triglycerides but not LDL cholesterol and an EPC phenotype that was assayed using a *Analyses were performed in a sample of 4497 participants in the Framingham Heart Study, among whom 419 incident MI events occurred over 36 years of follow-up. HRs correspond to the minor allele; thus, HR Ͻ1.0 denotes that the major allele is associated with higher MI risk. different culture method. 12 Furthermore, experimental in vitro and in vivo data have identified mechanisms by which statins may affect EPC phenotypes in the absence of any lipidlowering effects. For instance, statins have been shown to promote EPC differentiation and survival in vitro by modulating cell cycle regulation via the PI3K/Akt pathway 45 ; in a mouse model of MI, statins were also observed to promote EPC mobilization in an endothelial nitric oxide synthasedependent fashion. 46 With the exception of an association between CFUs and triglycerides, CFUs in our sample were not significantly associated with other metabolic traits, such as body mass index. CFUs also were not related to the presence of diabetes, although our analysis of this association may have been underpowered. Despite an inverse relation with Framingham risk score, CFUs were not associated with prevalent CVD in our sample; however, our ability to detect such an association may have been limited by the relatively low prevalence of CVD in our study cohort.
Genetic Determinants
Prior investigations of genetic determinants have been limited to candidate gene studies, with particular focus on variants associated with CXC chemokine receptor 4 (CXCR4). 47 In our genome-wide association data, significant relations of CFUs with CXCR4 gene variants were not observed (Pϭ0.28). On the other hand, we discovered common genetic variants at 2 novel loci, with probability values as low as 3.25ϫ10 Ϫ7 for association with CFUs. Although these loci must be replicated in independent cohorts, they represent potentially novel mechanisms underlying variation in CFU number.
Interestingly, the SLC22A3-LPAL2-LPA locus is a replicated susceptibility locus for MI. 48 In our sample, variants in SLC22A3 were associated with both CFUs (lowest Pϭ4.9ϫ10 Ϫ7 ) and MI risk (lowest Pϭ1.1ϫ10 Ϫ4 ). These data raise the possibility that variants at this locus influence MI risk at least partly through effects on angiogenic cell function. Although the variants in our study were within SLC22A3, multiple variants within or near SLC22A3, LPA, and LPAL2 were in LD (r 2 Ͼ0.80). LPA codes for apolipoprotein(a), a component of lipoprotein(a) and a known risk factor for coronary disease. 49, 50 LPAL2 encodes a structurally related isoform of apolipoprotein(a), and SLC22A3 encodes an organic cation transporter. 51 The potential contribution of any of these proteins to the pathogenesis of cardiovascular disease remains unclear. The 1q41 locus contains MOSC1 (MOCO sulfurase C-terminal domain containing-1). 51 Variants at this locus were not associated with MI.
Several lines of evidence link lower progenitor cell quantity and atherosclerosis. Experimental studies have demonstrated that bone marrow-derived EPC phenotypes can travel to and repair the endothelium at sites of intimal damage as well as stimulate new vessel growth, 52 though a recent study found that bone marrow-derived or circulating cells made minimal contributions to endothelial cells in atherosclerotic plaque. 9 In humans, several studies have reported an association between lower circulating CFUs and prevalent CVD. 17 In the present study, alleles at the SLC22A3-LPAL2-LPA locus that were associated with lower CFUs were also related to MI with the expected direction of effect; in general, the top SNPs at this locus that were associated with lower CFUs were also highly correlated with the top SNPs associated with increased risk of MI. These data are consistent with the hypothesis that lower circulating progenitors promote MI risk, although we cannot exclude the alternative scenario that SLC22A3-LPAL2-LPA variants promote subclinical atherosclerosis, which then leads to lower CFUs. Further studies are needed to test the hypothesis that reduced CFUs promotes atherosclerosis susceptibility via reduced vasculogenic or vascular repair potential.
Limitations
Several limitations of our study merit consideration. Culturebased methods for identifying EPC phenotypes are intended to promote proliferation of cells with endothelial-specific lineage; however, these methods are variable in technique as well as their ability to isolate cells that can form de novo blood vessels. 22 Although distinct from late-outgrowth endothelial colonies that are able to differentiate into mature endothelial cells, as reported by Yoder et al, 22 the earlyoutgrowth CFUs measured in this study have previously been shown to have hematopoietic activity, and their formation is dependent on known angiogenic cell populations such as monocytes and T cells. 3 Notwithstanding their recognized angiogenic potential, 40 however, CFUs probably comprise a heterogeneous population of cells with potentially distinct physiological properties. 22 Thus, further stratifying CFUs based on surface antigens, markers of senescence, and/or migratory capacity could provide additional insights. Because we studied an ambulatory, community-based cohort, the prevalence of prior CVD was low, limiting our ability to assess the cross-sectional relation between CFU number and CVD that has been reported by others. An important limitation of our genetic analyses is the lack of a replication sample, due in large part to the uniqueness of measuring CFUs in large samples with potential for genotyping. Although the association between the SLC22A3-LPAL2-LPA variants and MI risk has been replicated in other studies, the association of these variants with CFUs also requires replication. EPCrelated traits have been assessed in very few large samples because they are difficult to measure and require specialized specimen handling. In future prospective cohorts, incorporation of specific, standardized protocols for obtaining samples suitable for endothelial progenitor assessment and other cell-based phenotyping appears warranted. Last, our sample was limited to white individuals of European ancestry, limiting the generalizability of these findings to other racial/ ethnic groups.
Conclusion
We investigated the clinical and genetic determinants of CFUs in a large, community-based cohort. We found modest correlations between CFUs and cardiovascular risk factor burden, including the Framingham Risk Score. Furthermore, we identified common genetic variants that may influence CFU variation. Variants at one of these loci, SLC22A3-LPAL2-LPA, were associated with both decreased CFUs and increased risk for MI. Together, these findings raise the possibility that lower CFU number contributes to increased cardiovascular risk, potentially through mechanisms distinct from traditional cardiovascular risk factors. Given the sometimes conflicting studies that may be found in the EPC literature, 8 our data on a carefully characterized earlyoutgrowth CFU phenotype in a large community sample, coupled with genetic analyses, provide a foundation for formulating additional hypotheses about the determinants and function of angiogenic cells. Additional clinical and mechanistic studies are necessary to explore further the role of specific CFUs and angiogenic cell populations in both acquired and inherited cardiovascular risk.
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